Quick Dispatch:
Your surmount studies tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount studies tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients ships.
Need Help?
Questions about surmount studies tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount studies tirzepatide EASD 22: SURMOUNT-MMO: Tirzepatide in Obese Type II Diabetes Patients in your area.
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
23.70
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
26.55
SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeks
24.18
The SURMOUNT-MAINTAIN trial will help answer the question of what to do with the obesity medication dose to maintain weight loss long-term
28.19
Diabetes & Weight Loss Drug Tirzepatide Now Approved for OSA (Obstructive Sleep Apnea)
20.33
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity
20.42
Mounjaro (tirzepatide): Uses, Side Effects, Dosage & More
28.51
